A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Seminars in Oncology

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2003.08.013PMID 14613032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

  2004cited by this paper
• Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

  2001cited by this paper
• Abnormal pressure-natriuresis in hypertension: role of nitric oxide.

  2000cited by this paper
• Vascular endothelial growth factor: molecular and biological aspects.

  1999cited by this paper
• Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway*

  1999cited by this paper
• VEGF(165) mediates glomerular endothelial repair.

  1999cited by this paper
• Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.

  1999cited by this paper
• Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation.

  1998cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.

  1997cited by this paper
• Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

  1997cited by this paper
• Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

  1996cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

  1995cited by this paper
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

  1995cited by this paper
• Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool.

  1995cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma.

  1992cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance.

  2025cites this paper
• Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs

  2025cites this paper
• Desmoplastic small round cell tumor: A case report

  2025cites this paper
• Molecular Subtypes and Biomarker-based Detection of Breast Cancer: Challenges and Future Perspectives

  2025cites this paper
• Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer

  2025cites this paper
• Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer

  2024cites this paper
• Efficient drug delivery potential and antimicrobial activity of biocompatible hydrogels of dextrin/Na-alginate/PVA

  2024cites this paper
• The interaction of platelet-related factors with tumor cells promotes tumor metastasis

  2024cites this paper
• Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers

  2024cites this paper
• Microsphere-Enabled Modular Formation of Miniaturized In Vitro Breast Cancer Models.

  2023cites this paper
• Hypoxia signaling in cancer: Implications for therapeutic interventions

  2023cites this paper
• A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer

  2023cites this paper
• Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity

  2023cites this paper
• Novel delivery of sorafenib by natural killer cell-derived exosomes-enhanced apoptosis in triple-negative breast cancer.

  2023cites this paper
• Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer

  2023cites this paper
• Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential.

  2022cites this paper
• Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

  2022cites this paper
• Modulation of Tumor Vasculature Network: Key Strategies

  2022cites this paper
• Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report

  2022cites this paper
• Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review)

  2021cites this paper
• Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

  2021cites this paper
• A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers

  2021cites this paper
• Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

  2021cites this paper
• B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine

  2020cites this paper
• Designing clinical studies for biomarker discovery: The Design criteria

  2020cites this paper
• Microenvironmental Heterogeneity Among Triple-Negative Breast Cancer Subtypes and the Promise of Precision Medicine

  2020cites this paper
• Cardio-Oncology

  2020cites this paper
• Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study

  2020cites this paper
• Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.

  2019cites this paper
• Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

  2019cites this paper
• Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

  2019cites this paper
• The Value of Anti-angiogenics in Breast Cancer Therapy

  2019cites this paper
• Therapeutic Options for Metastatic Breast Cancer.

  2019cites this paper
• Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.

  2019cites this paper
• Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer

  2018cites this paper
• Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model

  2018cites this paper
• The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer

  2018cites this paper
• Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice

  2018cites this paper
• Tanshinone II A improves distribution and anti-tumor efficacy of pegylated liposomal doxorubicin via normalizing the structure and function of tumor vasculature in hepa1-6 hepatoma mice model

  2018cites this paper
• Combinational drug delivery using nanocarriers for breast cancer treatments: A review.

  2018cites this paper
• Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer

  2018cites this paper
• The dark side of tumor-associated endothelial cells.

  2018cites this paper
• Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti-angiogenic treatment

  2018cites this paper
• First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

  2017cites this paper
• Strategies to design clinical studies to identify predictive biomarkers in cancer research.

  2017cites this paper
• Acute and chronic effects of anti-cancer agents on cardiac mitochondrial function

  2017cites this paper
• The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.

  2017cites this paper
• 6.01 – Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R

  2017cites this paper
• Recent Advances in Angiogenesis Assessment Methods and their Clinical Applications

  2017cites this paper
• The Value of Antiangiogenics in Breast Cancer Therapy

  2017cites this paper
• Vessel pruning or healing: endothelial metabolism as a novel target?

  2017cites this paper
• A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers

  2017influential citation
• Bevacizumab Treatment for Solid Tumors

  2017cites this paper
• The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis

  2017cites this paper
• An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs

  2017cites this paper
• Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives

  2017cites this paper
• Targeting the Breast Cancer Kinome

  2017cites this paper
• Clinical results of randomized trials and ‘real-world’ data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research

  2017cites this paper
• Comparison of Internal Mammary Artery and Lateral Thoracic Artery Width in Patients with Benign and Malignant Breast Tumors

  2017cites this paper
• Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer.

  2017cites this paper
• Treatment of Hypertension in Patients Receiving Cancer Therapy

  2017cites this paper
• Bevacizumab Therapy for Pilomyxoid Astrocytoma

  2017cites this paper
• Ten years of anti-vascular endothelial growth factor therapy

  2016cites this paper
• Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis

  2016cites this paper
• Population pharmacokinetics of bevacizumab in cancer patients with external validation

  2016cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Antiangiogenic mechanisms and factors in breast cancer treatment

  2016cites this paper
• Angiogenesis Inhibition in Breast Cancer

  2016cites this paper
• Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer

  2016cites this paper
• Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

  2016cites this paper
• A Review on Bevacizumab: An Anti-Cancer Drug

  2016cites this paper
• Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy

  2016cites this paper
• The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better

  2016cites this paper
• Targeted Therapies in Triple-Negative Breast Cancer

  2015cites this paper
• A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

  2015cites this paper
• Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer

  2015cites this paper
• Angiogenesis Inhibitors in the Treatment of Breast Cancer: Exploring Avenues of New Therapeutic Targets

  2015influential citation
• Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography

  2015cites this paper
• Multifunctional Polymeric Nano-Carriers in Targeted Drug Delivery

  2015cites this paper
• The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.

  2015cites this paper
• SYNTHETIC LETHALITY OF CDK INHIBITION AND DOXORUBICIN IN TRIPLE-NEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION

  2015cites this paper
• Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET

  2015cites this paper
• Targeting the tumor vasculature to enhance T cell activity

  2015cites this paper
• Applications of Nanoparticles for Anticancer Drug Delivery: A Review.

  2015cites this paper
• Current opinion on bevacizumab on endometrial cancer treatment

  2015cites this paper
• Hypoxia and angiogenesis: from primary tumor to bone metastasis

  2015cites this paper
• A novel in vivo tumor oxygen profiling assay: Combining functional and molecular imaging with multivariate mathematical modeling

  2015cites this paper
• Mechanisms of action and resistance to anti-angiogenic small-molecule tyrosine kinase inhibitors in preclinical breast cancer and pancreatic neuroendocrine tumor mouse models

  2015cites this paper
• Bevacizumab: A dose review.

  2015cites this paper
• Use of bevacizumab in recurrent glioblastoma.

  2015cites this paper
• Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy

  2015cites this paper
• Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)

  2015cites this paper
• Contrast-enhanced ultrasound with perflubutane in the assessment of anti-angiogenic effects: early prediction of the anticancer activity of bevacizumab in a mouse xenografted model.

  2015cites this paper
• NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity‐modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer

  2015cites this paper
• Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody

  2014cites this paper
• Light Mediated Drug Delivery Using Photocaged Molecules and Photoswitchable Peptides

  2014cites this paper
• Physical Biology of Cancer Host endothelial S 1 PR 1 regulation of vascular permeability modulates tumor growth

  2014cites this paper
• Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth.

  2014cites this paper
• Desmoplastic small round cell tumor: a case report

  2014cites this paper
• ANGIOSTATIC PROPERTY OF CHITOSAN ACETATE IN THE CHICK CHORIOALLANTOIC MEMBRANE (CAM), IN OVO

  2014cites this paper